Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication

 
• By Joseph Haas
  
3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Kite obtains its second FDA approval for cell therapy Tecartus
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip